Philippe Lienard, Independent CMC and technology consultant

Languages

English
Native or bilingual
Spanish
Basic

Workplace preferences

Can work on-site

Paris (up to 50km)

AB Consulting
Independent CMC and technology consultant
PHARMACEUTICALS INDUSTRY
April 2022 - Today (4 years and 3 months)
Paris, France
- Consultancy for small biopharma compagnies e.g., Epimonipharm (USA based startup in health life), ICM (small molecules targeting brain cancer), Corteria (peptides development), and Aisa therapeutics (terpenes against inflammation).
Sanofi Research - Vitry
CMC project leader
PHARMACEUTICALS INDUSTRY
September 2017 - March 2024 (6 years and 6 months)
Vitry-sur-Seine, France
- Assumed a lead role in research and development teams as CMC expert.
- Successful elaboration of strategic plans to support project transitions from research to pre-clinical development phase.
- Applied several innovations and up-to-date technologies for the new chemical entities, e.g. small molecules and peptides.
- Business plan for a European unique nanoparticle manufacturing platform for clinical use.
o Key accomplishment: elaboration of integrated CMC strategies drug substance/drug product up to FIM and PoC.
Sanofi Research
Business development
PHARMACEUTICALS INDUSTRY
March 2014 - July 2018 (4 years and 4 months)
Vitry-sur-Seine, France
- Business plan for a European unique nanoparticle manufacturing platform for clinical use.
o Key achievement in this role: asset sale contract with an external partner V Nano company (320 k€).

Check out Philippe's experience

Be the first to recommend Philippe

Help this freelancer shine by sharing your experience working together.

A

Agatha Frydrych

Backend Java Software Engineer

4.7

(3)

2

B

Baptiste Duhen

Fullstack developer

4.6

(4)

5

A

Amed Hamou

Senior Lead Developer

4

(2)

7

A

Audrey Champion

Web developer

4.3

(3)

4

Signup to reveal

Ph D in Organic Chemistry University Paris XI - Orsay - France
University Paris XI
1991
- Asymmetric synthesis of biologically active compounds related to podophyllotoxin and steganon to discover new potential anticancer. ICSN/ CNRS - Gif-sur-Yvette (Professor H.-P. Husson)